Rip-off..?

Valeant Pharmaceuticals bought the rights to a pair of life-saving heart drugs. The same day, their list prices rose by 525% and 212%.
Neither of the drugs, Nitropress or Isuprel, was improved as a result of costly investment in lab work and human testing, Valeant said. Nor was manufacture of the medicines shifted to an expensive new plant. The big change: the drugs’ ownership.

More pharmaceutical companies are buying drugs that they see as undervalued, then raising the prices. It is one of a number of industry tactics, along with companies regularly upping the prices of their own older medicines and launching new treatments at once unheard of sums, driving up the cost of drugs.

Valiant received subpoenas from federal prosecutors seeking information related to how it prices drugs, distributes them and helps patients afford the medicines.
The subpoenas also seek information and documents from the Canada-based drug company regarding information it provided to the Centers for Medicare and Medicaid Services.

This is a Rip-off plan by all means. Prices are over the top. The big one buy the little and off they go. Request Tax reduction for business competitiveness and then create a fictitious domicile in Ireland or so.

The market must have competition in the pharmaceuticals area.   Just a thought.